目录
更新日期:2025年10月10日
姓 名 丁轶 性 别
民 族 回族 导师层次 博士导师
技术职称 教授 导师类型 学术&专业型
最后学历 博士研究生毕业 最后学位 医学博士学位
行政职务 副主任 Email dingyi197980@126.com
工作单位 南方医科大学南方医院 邮政编码 510515
个人简介

    丁轶,南方医科大学南方医院放疗科科室副主任,腹部肿瘤组组长,教授,副主任医师,博士生导师,博士后合作导师。研究方向:消化系统肿瘤精准放疗及综合治疗;放射性肠损伤的临床、基础与转化研究;免疫抑制微环境形成的分子靶标和放射抵抗性的基础与转化研究。

    2003.6第一军医大学毕业;2008.6获南方医科大学医学博士学位。2008.7南方医科大学南方医院从事临床科研工作至今,历任住院医师,主治医师,2015年起任副主任医师。2016年起任医院放疗科胃肠癌亚专科组长。2019.11起任放疗科科室副主任。2018年4月于中国医学科学院肿瘤医院进修,2019年9月-10月赴美进修。近年来主要负责消化系统肿瘤的精确放射治疗及综合处理,为医院胃肠肿瘤MDT成员之一。

    近年来,主持国家自然科学基金5项,广东省自然科学杰出青年基金1项、广东省特支计划科技创新青年拔尖人才计划1项、广东省高校优秀青年教师培养项目及广州市“珠江科技新星”等人才计划项目各1项,其他省市级基金6项,累计获项目资助及配套经费330余万元。以一作/通讯作者在iMeta、Hepatology、Nature Communications、Journal of Hematology & Oncology、The ISME Journal、Journal of Advanced Research、Int Jradiat Oncol Biol Phys Int等杂志发表研究论文30余篇,累计IF>210。获得广东省自然科学奖一等奖1项、广东省科技奖进步一等奖及三等奖各1项,发明专利5项、实用新型专利1项;以第一负责人获省级教学奖2项,校级教学奖8项。目前兼任兼任广东省肝脏病协会放疗专委会主任委员、广东省医学会放射防护学分会副主任委员、中国研究型医院学会肿瘤放射生物与多模态诊疗专委会委员、中华医学会放射肿瘤治疗分会青年学组委员、广东省医院协会放疗专委会副主任委员、广东省医院协会放射治疗科管理专委会副主任委员、广东省女医师协会放射肿瘤学专业委员会常务委员、中国抗癌协会中西整合结直肠癌专业委员会委员、广东省临床医学学会肿瘤学专业委员会常务委员等学术任职。先后获得广东省杰出青年、广东省特支计划-科技创新青年拔尖人才、广东省杰出青年医学人才、广东省优秀青年教师、广东省实力中青年医生、广州市珠江科技新星等多项荣誉称号。

 
研究领域

研究方向:消化系统肿瘤:1. 消化系统肿瘤放射治疗及综合治疗;2.放射性肠损伤的临床、基础及转化研究 ;3. 免疫抑制微环境形成的分子靶标和机制研究;4. 辐射敏感性的基础及转化研究;


 

个人成果

(1)Yu L#, Guo Q#, Gu X#, Yi Ding*(末位通讯作者), Impact of gut microbiome on radiotherapy and immunotherapy efficacy in microsatellite-stable colorectal cancer: role of propionic acid and B. fragilis. [J], British Journal of Cancer. 2025 Jul; 10.1038/s41416-025-03105-2(小类2区,2025IF=6.8)

(2)Yu L#, Chen Z#, Yin S#, Yi Ding*(末位通讯作者),Gut-derived Lactobacillus from exceptional responders mitigates chemoradiotherapy-induced intestinal injury through methionine-driven epigenetic modulation. [J], iMeta. 2025 May;10.1002/imt2.70043(小类1区,2025IF=33.2)

(3)Wang Y#, Wang X#, Chen Z#, Yi Ding*(末位通讯作者). Akkermansia muciniphila exacerbates acute radiation-induced intestinal injury by depleting mucin and enhancing inflammation. [J], The ISME Journal. 2025 Apr; 0.1093/ismejo/wraf084(小类1区,2025IF=10.7)

(4)Wang Z#, Zhang X#, Luo Y#, Yi Ding*(末位通讯作者),Therapeutic targeting of ARID1A-deficient cancer cells with RITA (Reactivating p53 and inducing tumor apoptosis. [J], Cell Death & Disease. 2024 May; 10.1038/s41419-024-06751-1(小类1区,2024IF=19.8)

(5)Xie Y#, Liu Y#, Lin M#, Yi Ding*(末位通讯作者),Targeting ATM enhances radiation sensitivity of colorectal cancer by potentiating radiation-induced cell death and antitumor immunity. Journal of Advanced Research. [J], 2024 Dec; 10.1016/j.jare.2024.12.023(小类1区,2024IF=13)

(6)Zheng Y#, Zhan Y#, Zhang Y#, Yi Ding*(末位通讯作者),Hexokinase 2 confers radio-resistance in hepatocellular carcinoma by promoting autophagy-dependent degradation of AIMP2. [J], Cell Death & Disease. 2023 Aug; 10.1038/s41419-023-06009-2(小类2区,2023IF=9.8)

(7)Liu K#,, Wang H#,, Zhou J#,, Yi Ding*(末位通讯作者), HMGB1 in exosomes derived from gastric cancer cells induces M2-like macrophage polarization by inhibiting the NF-κB signaling pathway. [J], Cell Biology International. 2023 Dec; 10.1002/cbin.12110(小类4区,2023IF=3.5)

(8)Weng J#, Zhang Y#, Liang W#, Yi Ding*(末位通讯作者), Downregulation of CEMIP enhances radiosensitivity by promoting DNA damage and apoptosis in colorectal cancer. [J], Medical Oncology. 2023 Jan; 10.1007/s12032-022-01940-4(小类4区,2023IF=3.3)

(9)Ye F#, Xie Y#, Lin M#, Yi Ding*(共同通讯作者)KIAA1549 promotes the development and chemoresistance of colorectal cancer by upregulating ERCC2. Molecular and Cellular Biochemistry. [J], 2023 May; 10.1007/s11010-023-04751-x(小类3区,2023IF=3.7)

(10)Yuan Fang#, Yi-Zhi Zhan#, Yu-wen-Xie#, Yi Ding*(共同通讯作者),De-hua Wu*,Integration of glucose and cardiolipin anabolism confers radiation resistance of HCC.[J], HEPATOLOGY., 2022 Jun;75(6):1386-1401.(小类1区,2022IF=17.298)

(11)Li Y#, Shen Z#, Chai Z#, Yi Ding*(共同通讯作者),Targeting MS4A4A on tumour-associated macrophages restores CD8+ T-cell-mediated antitumour immunity. Gut. [J],2023 Dec; 10.1136/gutjnl-2022-329147(小类1区,2023IF=25.8)

(12)Yuan Fang#, Zhi-Yong Shen#,De-Hua Wu*, Yi Ding*(通讯作者), CD36 inhibits β-catenin/c-myc-mediated glycolysis through ubiquitination of GPC4 to repress colorectal tumorigenesis[J], Nat Commun., 2019 4;10(1):3981.(小类1区,2019IF=11.878)

(13)Zhan Y#, Zhang Z#, Liu Y#, Fang Y#, Liang L, Ding Y*(通讯作者). NUPR1 contributes to radiation resistance by maintaining ROS homeostasis via AhR/CYP signal axis in hepatocellular carcinoma. BMC Med. 2022 Oct 19;20(1):365.(小类1区,2022IF=11.150)

(14)Ni W., Chen Lh*, Ding Y*.(通讯作者),A novel lncRNA uc.134 represses hepatocellular carcinoma progression by inhibiting CUL4A-mediated ubiquitination of LATS1[J], Journal of Hematology & Oncology,2017,10(1): 1 ~ 17.(小类1区,2017IF=7.333)

(15)Lu Yu#, Qi-qing Guo#, Zi-qian Luo#, Yong-jia Wang#, Zhen-hui Chen*, Yi Ding*(共同通讯作者), Yao-wei Zhang*,TXN inhibitor impedes radioresistance of colorectal cancer cells with decreased ALDH1L2 expression via TXN/NF-κB signaling pathway[J],Br J Cancer., 2022 Sep 1; 127(4): 637–648.(小类2区,2022IF=9.075)

(16)Zheng Y#, Zhan Y#, Zhang Y#, Zhang Y, Liu Y, Xie Y, Sun Y, Qian J, Ding Y*, Ding Y*(共同通讯作者), Fang Y*. Hexokinase 2 confers radio-resistance in hepatocellular carcinoma by promoting autophagy-dependent degradation of AIMP2. Cell Death Dis. 2023 Aug 1;14(8):488. (小类2区,2023IF=9.0)

(17)Wang Z#, Zhang X#, Luo Y, Song Y, Xiang C, He Y, Wang K, Yu Y, Wang Z, Peng W, Ding Y*(共同通讯作者), Liu S*, Wu C*. Therapeutic targeting of ARID1A-deficient cancer cells with RITA (Reactivating p53 and inducing tumor apoptosis). Cell Death Dis. 2024 May 29;15(5):375.(小类2区,2024IF=8.1)

(18)Wang Y#, Zhang Y#, Wang Z#, Yu L, Chen K, Xie Y, Liu Y, Liang W, Zheng Y, Zhan Y*, Ding Y*(通讯作者). The interplay of transcriptional coregulator NUPR1 with SREBP1 promotes hepatocellular carcinoma progression via upregulation of lipogenesis. Cell Death Discov. 2022 Oct 28;8(1):431.(小类2区,2022IF=7.109)

(19)Zhiyong Shen#, Xiaochuang Feng#, Yuan Fang#, Yi Ding* (共同通讯作者)and Haijun Deng*.POTEE drives colorectal cancer development via regulating SPHK1/p65 signaling. Cell Death Dis.2019 Nov 13;10(11):863.(小类2区,2019IF=5.959)

(20)Fang He#, Huai-Qiang Ju#, Yi Ding#(共同一作), Jaffer A. Ajani* and Xiang-Bo Wan*.Association between adjuvant chemotherapy and survival in patients with rectal cancer and pathological complete response after neoadjuvant chemoradiotherapy and resection.Br J Cancer.2020 Oct;123(8):1244-1252. (小类2区,2020IF=5.791)

(21)Fang He#, Li Yu#, Yi Ding#(共同一作),Jaffer A. Ajani* and Xiang-Bo Wan*. Effects of neoadjuvant chemotherapy with or without intensity-modulated radiotherapy for patients with rectal cancer.Cancer Sci.2020 Aug 29.(小类2区,2020IF=4.966)

(22)Yu Lu#, Ye Feng#, Li Yi-Yi#, Chen Long-hua*, Ding Yi*(共同通讯作者), Chen Ke-Li*, Histone Methyltransferase SETDB1 Promotes Colorectal Cancer Proliferation through the STAT1-CCND1/CDK6 Axis[J], Carcinogenesis. 2020 Jul 10;41(5):678-688. (小类2区,2020IF=4.603)

(23)Zhang Y#., Zheng L#., Ding Y#.(共同一作), Wang W*., Chen L*.,MiR-20a Induces Cell Radioresistance by Activating the PTEN/PI3K/Akt Signaling Pathway in Hepatocellular Carcinoma[J] ,Int J Radiat Oncol Biol Phys,2015,92(5): 1132 ~ 1140(小类2区,2015IF=4.495)